Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

A 68-Year-Old Man With Metastatic EGFR+ NSCLC

home / case-based-peer-perspectives / a-68-year-old-man-with-metastatic-egfr-nsclc

John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.

A 68-Year-Old Man With Metastatic EGFR+ NSCLC

EP. 1: A 68-Year-Old Man With Metastatic EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020

Watch

Improved Outcomes for Patients With EGFR+ NSCLC

EP. 2: Improved Outcomes for Patients With EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020

Watch

Molecular Testing for Newly Diagnosed NSCLC

EP. 3: Molecular Testing for Newly Diagnosed NSCLC

John Heymach, MD, PhD
May 21st 2020

Watch

Treatment Options for EGFR+ NSCLC

EP. 4: Treatment Options for EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020

Watch

Practical Implications of the RELAY Trial in EGFR+ NSCLC

EP. 5: Practical Implications of the RELAY Trial in EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020

Watch

Manageable Adverse Effects Associated With Treatments for EGFR+ NSCLC

EP. 6: Manageable Adverse Effects Associated With Treatments for EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020

Watch

Repeat Testing at Progression of EGFR+ NSCLC

EP. 7: Repeat Testing at Progression of EGFR+ NSCLC

John Heymach, MD, PhD
May 21st 2020

Watch

Changing Landscape of EGFR+ mNSCLC

EP. 8: Changing Landscape of EGFR+ mNSCLC

John Heymach, MD, PhD
May 21st 2020

Watch

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.